18 results on '"Griesinger, Frank"'
Search Results
2. Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023 with Focus on Targeted Therapies.
- Author
-
Acker, Fabian, Luan, Jingting, Soltani Germy, Puyan, Kemper, Marcel, Blasi, Miriam, Griesinger, Frank, Tufman, Amanda, Bleckmann, Annalen, Kropf-Sanchen, Cornelia, and Overbeck, Tobias Raphael
- Subjects
MEDICAL societies ,SMALL cell lung cancer ,ONCOLOGY ,NON-small-cell lung carcinoma ,ANNUAL meetings - Abstract
The article provides an overview of key findings from the 2023 European Society for Medical Oncology (ESMO) annual meeting in the field of thoracic oncology, specifically focusing on targeted therapies for non-small cell lung cancer (NSCLC). The studies discussed highlight the safety and efficacy of various targeted therapies, such as adagrasib plus pembrolizumab for patients with a specific genetic mutation, and the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel for other genetic mutations. The article acknowledges the positive outcomes observed in these trials but also emphasizes the need for further research and understanding of these therapies. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
3. Patient‐reported outcomes in advanced NSCLC before and during the COVID‐19 pandemic: Real‐world data from the German prospective CRISP Registry (AIO‐TRK‐0315).
- Author
-
Sebastian, Martin, Eberhardt, Wilfried E. E., von der Heyde, Eyck, Dörfel, Steffen, Wiegand, Jörg, Schiefer, Clemens, Losem, Christoph, Jänicke, Martina, Fleitz, Annette, Zacharias, Stefan, Kaiser‐Osterhues, Anja, Hipper, Annette, Dietel, Corinna, Bleckmann, Annalen, Benkelmann, Robin, Boesche, Michael, Grah, Christian, Müller, Annette, Griesinger, Frank, and Thomas, Michael
- Subjects
COVID-19 pandemic ,PATIENT reported outcome measures ,NON-small-cell lung carcinoma ,COVID-19 - Abstract
Patients with lung cancer under treatment have been associated with a high risk of COVID‐19 infection and potentially worse outcome, but real‐world data on patient‐reported outcomes (PROs) are rare. We assess patients' characteristics and PROs before and during the COVID‐19 pandemic in an advanced non‐small cell lung cancer (NSCLC) cohort in Germany. Patients with locally advanced or metastatic NSCLC from the prospective, multicentre, observational CRISP Registry (NCT02622581) were categorised as pre‐pandemic (March 2019 to Feb 2020, n = 1621) and pandemic (March 2020 to Feb 2021, n = 1317). From baseline to month 15, patients' health‐related quality of life (HRQoL) was assessed by FACT‐L, anxiety and depression by PHQ‐4. Association of pandemic status with time to deterioration (TTD) in QoL scales adjusted for potential covariates was estimated using Cox modelling. PROs were documented for 1166 patients (72%) in the pre‐pandemic, 979 (74%) in the pandemic group. Almost 60% of patients were male, median age was 66 years, comorbidities occurred in 85%. Regarding HRQoL, mean‐change‐from‐baseline plots hardly differed between both samples. Approximately 15%–21% of patients reported anxiety, about 19%–27% signs of depression. For the pandemic group, TTD was slightly, but statistically significantly, worse for the physical well‐being‐FACT‐G subscale (HR 1.15 [95%CI 1.02–1.30]) and the anxiety‐GAD‐2 subscale (HR 1.14 [95%CI 1.01–1.29]). These prospectively collected real‐world data provide valuable insights into PROs before and during the COVID‐19 pandemic in advanced NSCLC. For the patients, the pandemic seemed to be less of a burden than the disease itself, as there was a considerable proportion of patients with anxiety and depression in both groups. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer
- Author
-
Stratmann, Jan A., Michels, Sebastian, Hornetz, Sofia, Christoph, Daniel C., Sackmann, Sandra, Spengler, Werner, Bischoff, Helge, Schäfer, Monica, Alt, Jürgen, Müller, Annette, Laack, Eckart, Kimmich, Martin, Griesinger, Frank, and Sebastian, Martin
- Published
- 2018
- Full Text
- View/download PDF
5. Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis
- Author
-
Hardtstock, Fränce, Myers, David, Li, Tracy, Cizova, Diana, Maywald, Ulf, Wilke, Thomas, and Griesinger, Frank
- Published
- 2020
- Full Text
- View/download PDF
6. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
- Author
-
Papachristofilou, Alexandros, Hipp, Madeleine M., Klinkhardt, Ute, Früh, Martin, Sebastian, Martin, Weiss, Christian, Pless, Miklos, Cathomas, Richard, Hilbe, Wolfgang, Pall, Georg, Wehler, Thomas, Alt, Jürgen, Bischoff, Helge, Geißler, Michael, Griesinger, Frank, Kallen, Karl-Josef, Fotin-Mleczek, Mariola, Schröder, Andreas, Scheel, Birgit, Muth, Anke, Seibel, Tobias, Stosnach, Claudia, Doener, Fatma, Hong, Henoch S., Koch, Sven D., Gnad-Vogt, Ulrike, and Zippelius, Alfred
- Published
- 2019
- Full Text
- View/download PDF
7. Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts.
- Author
-
Chouaid, Christos, Thomas, Michael, Debieuvre, Didier, Durand-Zaleski, Isabelle, Zacharias, Stefan, Bosquet, Lise, Groth, Annika, Fleitz, Annette, Calleja, Alan, Patel, Sonya, Lacoin, Laure, Daumont, Melinda J., Penrod, John R., Carroll, Robert, Waldenberger, Daniela, Cotté, François-Emery, Audigier-Valette, Clarisse, and Griesinger, Frank
- Subjects
LUNG cancer prognosis ,DRUG efficacy ,LUNG cancer ,SCIENTIFIC observation ,METASTASIS ,TREATMENT duration ,CANCER patients ,NIVOLUMAB ,DESCRIPTIVE statistics ,LONGITUDINAL method ,EVALUATION - Abstract
Simple Summary: There is a need to better understand the effectiveness of new treatments, such as the recently approved nivolumab, in patients with locally advanced or metastatic non-small cell lung cancer in clinical practice. This study aims to report the characteristics and outcomes of 2784 patients with locally advanced or metastatic non-small cell lung cancer receiving nivolumab in second-line or later in France (ESME-AMLC) and Germany (CRISP) between 2015 and 2020. Two-year survival rates were 26.7% in patients with tumors with squamous histology and 32.8% in patients with non-squamous/others histologies in ESME-AMLC, and 20.9% and 18.9%, respectively, in CRISP. Poorer performance score and shorter duration from the previous line of therapy initiation were significantly associated with shorter treatment duration with nivolumab and overall survival. These real-world data provide insight into the characteristics of patients receiving nivolumab in France and Germany and confirm the efficacy of nivolumab previously observed in clinical trials. This study reports characteristics and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (aNSCLC) receiving nivolumab in second-line or later (2L+) in France and Germany between 2015 and 2020. Patients with aNSCLC (stage IIIB–C/IV) receiving nivolumab in 2L+ were included from the retrospective Epidemiological Strategy and Medical Economics of Advanced and Metastatic Lung Cancer cohort (ESME-AMLC, France; 2015–2019) and Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP, Germany; 2016–2020). Overall, 2262 ESME-AMLC and 522 CRISP patients were included. Median treatment duration (95% confidence intervals) was 2.8 months (2.5–3.2) in squamous and 2.5 months (2.3–2.8) in non-squamous/others patients in ESME-AMLC, and 2.3 months (1.4–3.1) and 2.3 months (2.0–2.8), respectively in CRISP. One-year and two-year overall survival (OS) were 47.2% and 26.7% in squamous and 50.8% and 32.8% in non-squamous/others patients in ESME-AMLC, and 43.1% and 20.9%, and 37.7% and 18.9%, respectively in CRISP. Poorer performance score and shorter time from start of previous line of therapy initiation were significantly associated with shorter treatment duration and OS. This study confirms, in real-world clinical databases, the efficacy of nivolumab previously observed in clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Afatinib as first-line treatment in patients with EGFR -mutated non-small cell lung cancer in routine clinical practice.
- Author
-
Brückl, Wolfgang M., Reck, Martin, Griesinger, Frank, Schäfer, Harald, Kortsik, Cornelius, Gaska, Tobias, Rawluk, Justyna, Krüger, Stefan, Kokowski, Konrad, Budweiser, Stephan, Ficker, Joachim H., Hoffmann, Christopher, Schüler, Andrea, and Laack, Eckart
- Abstract
Background: Lung cancer is a leading cause of cancer-related death in Germany and worldwide. Non-small cell lung cancer (NSCLC) comprises ~80% of lung cancer diagnoses; in White patients, around 10% of NSCLC cases are epidermal growth factor receptor mutation-positive (EGFR m+). Head-to-head clinical trials have demonstrated superior efficacy with second-/third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) versus first-generation EGFR TKIs in EGFR m+ NSCLC. Data from routine clinical practice are necessary to confirm that clinical trial findings are transferable to real-world populations. Methods: In NCT02047903, a prospective non-interventional study in Germany, patients with EGFR m+ NSCLC received first-line afatinib until disease progression or intolerable adverse events. Key objectives were progression-free survival (PFS) rate at 12 months, objective response rate (ORR) and overall survival (OS). Safety/tolerability was also assessed. Results: Of 152 patients, 106 (69.7%) were female, 20 (13.1%) patients had an uncommon EGFR mutation and 51 patients (33.6%) had brain metastases. A starting dose of <40 mg was received by 39 (25.7%) patients. Overall, the 12-month PFS rate was 50.2% while the median PFS was 12.2 months. The ORR was 74.6% and the median OS was 30.4 months. In patients with brain metastases and uncommon mutations, the median PFS was 10.5 and 10.7 months, and the ORR was 77.3% and 83.3%, respectively. Treatment effectiveness was similar in patients with a starting dose of <40 mg (median PFS: 16.4 months; ORR, 81.3%) and a starting dose of 40 mg (median PFS: 10.8 months; ORR, 72.1%). Adverse drug reactions were manageable and consistent with the known afatinib safety profile. Conclusion: The results support clinical trial data for afatinib in routine clinical practice, including in patients generally excluded from clinical trials. Outcomes were positive in patients with uncommon EGFR mutations and in those with brain metastases. Treatment benefit was also seen in patients receiving a <40 mg afatinib starting dose, supporting patient-tailored dosing. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Pralsetinib in patients with RET fusion–positive non-small-cell lung cancer: A plain language summary of the ARROW study.
- Author
-
Griesinger, Frank, Curigliano, Giuseppe, Subbiah, Vivek, Baik, Christina S, Tan, Daniel SW, Lee, Dae H, Misch, Daniel, Garralda, Elena, Kim, Dong-Wan, van der Wekken, Anthonie J, Gainor, Justin F, Paz-Ares, Luis, Liu, Stephen V, Kalemkerian, Gregory P, Bowles, Daniel W, Mansfield, Aaron S, Lin, Jessica J, Smoljanovic, Vlatka, Rahman, Ahmadur, and Zalutskaya, Alena
- Abstract
This is a summary of a research study called ARROW, which tested a medicine called pralsetinib in patients with non-small cell lung cancer (NSCLC), thyroid cancer, and other advanced solid tumours caused by a change in a gene called RET. For the purposes of this summary, only patients with NSCLC with a change in RET called fusion (RET fusion+) are highlighted. In total, 281 patients with RET fusion+ NSCLC had taken part in this study across the USA, Europe, and Asia. Patients were asked to take four pills (adding up to 400 mg) of pralsetinib each day and were checked for any changes in their tumours, as well as for any side effects. After an average of 8 months of treatment with pralsetinib, 72% of previously untreated patients and 59% of patients who had previously received chemotherapy had considerable shrinkage of their tumours. Among 10 patients with tumours which had spread to the brain (all of whom had received previous treatments), 70% had their tumours shrink greatly in the brain after treatment with pralsetinib. On average, patients lived with little to no tumour growth for 16 months. In previously untreated patients, the most common severe side effects that were considered related to pralsetinib treatment were decreased white blood cells (neutrophils and lymphocytes), increased blood pressure, and an increase in a blood protein called creatine phosphokinase. In previously treated patients, the severe side effects were decreased white blood cells (neutrophils, lymphocytes, and leukocytes), increased blood pressure, and low levels of red blood cells. In both untreated and previously treated patients, the most common severe side effects that required hospital attention were lung inflammation/swelling causing shortness of breath (pneumonitis) and lung infection (pneumonia). Overall, the ARROW study showed that pralsetinib was effective in shrinking tumours in patients with RET fusion+ NSCLC regardless of previous treatment history. The recorded side effects were expected in patients receiving this type of medicine. Clinical Trial Registration: NCT03037385 (ARROW) (ClinicalTrials.gov) [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
- Author
-
Griesinger, Frank, Eberhardt, Wilfried, Nusch, Arnd, Reiser, Marcel, Zahn, Mark-Oliver, Maintz, Christoph, Bernhardt, Christiane, Losem, Christoph, Stenzinger, Albrecht, Heukamp, Lukas C., Büttner, Reinhard, Marschner, Norbert, Jänicke, Martina, Fleitz, Annette, Spring, Lisa, Sahlmann, Jörg, Karatas, Aysun, Hipper, Annette, Weichert, Wilko, and Heilmann, Monika
- Subjects
- *
NON-small-cell lung carcinoma , *CANCER treatment , *EPIDERMAL growth factor receptors , *BIOMARKERS - Abstract
• The CRISP registry collects representative, nationwide data on NSCLC in Germany. • CRISP mirrors the treatment and disease trajectory of patients with advanced NSCLC. • Biomarker testing rates increased over time, yet are still improvable. • 17.7 % of the patients presented with a druggable alteration. • Median PFS was longer for patients with a druggable EGFR or ALK alteration. An increasing number of treatment-determining biomarkers has been identified in non-small cell lung cancer (NSCLC) and molecular testing is recommended to enable optimal individualized treatment. However, data on implementation of these recommendations in the "real-world" setting are scarce. This study presents comprehensive details on the frequency, methodology and results of biomarker testing of advanced NSCLC in Germany. This analysis included 3,717 patients with advanced NSCLC (2,921 non-squamous; 796 squamous), recruited into the CRISP registry at start of systemic therapy by 150 German sites between December 2015 and June 2019. Evaluated were the molecular biomarkers EGFR , ALK , ROS1 , BRAF , KRAS , MET , TP53 , RET , HER2 , as well as expression of PD-L1. In total, 90.5 % of the patients were tested for biomarkers. Testing rates were 92.2 % (non-squamous), 70.7 % (squamous) and increased from 83.2 % in 2015/16 to 94.2% in 2019. Overall testing rates for EGFR , ALK , ROS1 , and BRAF were 72.5 %, 74.5 %, 66.1 %, and 53.0 %, respectively (non-squamous). Testing rates for PD-L1 expression were 64.5 % (non-squamous), and 58.5 % (squamous). The most common testing methods were immunohistochemistry (68.5 % non-squamous, 58.3 % squamous), and next-generation sequencing (38.7 % non-squamous, 14.4 % squamous). Reasons for not testing were insufficient tumor material or lack of guideline recommendations (squamous). No alteration was found in 37.8 % (non-squamous), and 57.9 % (squamous), respectively. Most common alterations in non-squamous tumors (all patients/all patients tested for the respective biomarker): KRAS (17.3 %/39.2 %), TP53 (14.1 %/51.4 %), and EGFR (11.0 %/15.1 %); in squamous tumors: TP53 (7.0 %/69.1 %), MET (1.5 %/11.1 %), and EGFR (1.1 %/4.4 %). Median PFS (non-squamous) was 8.7 months (95 % CI 7.4–10.4) with druggable EGFR mutation, and 8.0 months (95 % CI 3.9–9.2) with druggable ALK alterations. Testing rates in Germany are high nationwide and acceptable in international comparison, but still leave out a significant portion of patients, who could potentially benefit. Thus, specific measures are needed to increase implementation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
- Author
-
Griesinger, Frank, Korol, Ellen E., Kayaniyil, Sheena, Varol, Nebibe, Ebner, Timo, and Goring, Sarah M.
- Subjects
- *
NON-small-cell lung carcinoma , *CANCER chemotherapy , *QUALITY of life - Abstract
• Overall survival was similar between cisplatin- and carboplatin-based chemotherapy. • Slightly greater probability of objective response for cisplatin-based chemotherapy. • Drug-related toxicity differed in carboplatin- and cisplatin-based chemotherapy. • Few studies compared health-related quality of life by platinum-based chemotherapy. Platinum-based chemotherapy is the mainstay of first-line (1L) therapy for advanced non-small cell cancer (NSCLC). The objective of this study was to evaluate the relative efficacy, safety, and health-related quality of life (HRQoL) of carboplatin- versus cisplatin-based chemotherapy in 1L NSCLC. A meta-analysis by the Cochrane group (2013) was updated. Systematic searches of CENTRAL, Medline, Embase, Latin American and Caribbean Health Sciences database, clinicaltrials.gov and conference proceedings were conducted to include randomized controlled trials (RCTs) published between 2013-January 2018 which compared carboplatin and cisplatin combined with: gemcitabine, vinorelbine, docetaxel, paclitaxel, irinotecan, or pemetrexed. Endpoints included overall survival (OS), one-year OS, objective response rate (ORR), grade 3/4 drug-related toxicities, and HRQoL. Twelve RCTs (2,048 patients) were identified from 4,139 records for inclusion in the meta-analysis. There were no significant differences in OS (hazards ratio [HR]: 1.08, 95% confidence interval [CI]: 0.96, 1.21) and one-year OS (relative risk [RR]: 0.97, CI: 0.89, 1.07) between carboplatin- and cisplatin-based chemotherapy. A small effect on ORR favouring cisplatin was detected (RR = 0.88; CI: 0.78, 0.99). Differences in drug-related toxicities were observed between carboplatin- and cisplatin-based chemotherapy for thrombocytopenia, anaemia, neurotoxicity, and the risk of nausea/vomiting. Three RCTs comparing HRQoL between carboplatin- and cisplatin-based chemotherapy found no significant differences. This updated evidence base corroborates findings of previous meta-analyses showing no difference in OS between carboplatin- and cisplatin-based chemotherapy, despite a slight benefit in ORR for cisplatin. Toxicity profiles should be considered alongside patients' comorbidities in the choice of therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
- Author
-
Krefting, Frederik, Basara, Nadezda, Schütte, Wolfgang, Späth-Schwalbe, Ernst, Alt, Jürgen, Thiel, Sebastian, Kimmich, Martin, Fischer, Jürgen R., Kurz, Sylke, Griesinger, Frank, and Christoph, Daniel C.
- Subjects
NON-small-cell lung carcinoma ,TREATMENT effectiveness ,IMMUNOTHERAPY - Abstract
Background: Anti-PD1 monoclonal antibody nivolumab is an approved therapy option for the treatment of advanced squamous cell non-small cell lung cancer (SQ-NSCLC) patients. Data outside clinical trials about therapy efficacy and safety in later therapy line treatments have rarely been described until now. Methods: We performed a retrospective data analysis of patients who were enrolled into the nivolumab Compassionate Use Program (CUP) in Germany. Sufficient clinical data of 40 patients were available for efficacy and safety analysis. Results: Overall, 47.5% of all treated patients were not affected by any adverse events (AEs); 17.5% of patients suffered from severe AEs. The 1-year survival rate was 61.3%. Estimated median progression-free survival (PFS) was 5.3 months. Patients who received nivolumab as third or later therapy line treatment (77.5%) achieved similar median PFS and 12-month overall survival rate of 52%. Conclusion: Our findings of immunotherapy treatment outside clinical trials support the results of studies in the past and confirm the efficacy and favorable toxicity profile of nivolumab treatment in advanced SQ-NSCLC patients. In addition, we can present some rarely described information about nivolumab treatment of heavily pretreated patients, which provides some evidence that immunotherapy could also be useful in later therapy lines. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
13. Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study.
- Author
-
Brueckl, Wolfgang M., Reck, Martin, Schäfer, Harald, Neben, Kai, Griesinger, Frank, Rawluk, Justyna, Krüger, Stefan, Kokowski, Konrad, Ficker, Joachim H., Möller, Miriam, Schueler, Andrea, and Laack, Eckart
- Abstract
Lung cancer is most common in older patients; despite this, older patients are historically under-represented in clinical studies. Here we present data from GIDEON, a study undertaken in Germany in patients with epidermal growth factor receptor mutation-positive (EGFR m+) non-small cell lung cancer (NSCLC) receiving first-line afatinib. GIDEON enrolled a high proportion of patients aged ≥70 years, providing an opportunity to study afatinib use in older patients. In GIDEON (NCT02047903), a prospective non-interventional study, patients with EGFR m+ NSCLC received first-line afatinib in routine clinical practice until disease progression, death or intolerable adverse events. Key objectives were twelve-month progression-free survival (PFS) rate and objective response rate (ORR). Overall survival (OS) and safety were also assessed. This post hoc analysis explores outcomes of patients grouped by age (≥70 and <70 years). In the 152 patients enrolled in GIDEON (69.7% female, 64.5%/22.4%/13.2% with Del19/L858R/other exon 18–21 mutations, 33.6% with brain metastases), the median age was 67 years (range 38–89) and 43.4% were aged ≥70 years. In the ≥70 years age group and the <70 years age group, twelve-month PFS rate was 58.9% and 43.9%, median PFS was 17.2 months and 10.6 months, ORR was 72.0% and 76.5%, twelve-month OS rate was 79.1% and 79.2%, 24-month OS rate was 52.0% and 61.7%, and median OS was 30.4 months and 27.4 months, respectively. In the ≥70 years age group and the <70 years age group, grade ≥3 adverse drug reactions (ADRs) were observed in 34.8% and 40.7% of patients, respectively; the most common were diarrhea (13.6% and 14.0%), acneiform dermatitis (7.6% and 7.0%), stomatitis (1.5% and 4.7%) and maculopapular rash (1.5% and 4.7%). Patients with EGFR m+ NSCLC aged ≥70 years showed clinical benefit from first-line afatinib with no unexpected safety signals, supporting the use of afatinib in this setting. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
- Author
-
Heigener, David F., Schumann, Christian, Sebastian, Martin, Sadjadian, Parvis, Stehle, Ingo, Märten, Angela, Lüers, Anne, Griesinger, Frank, Scheffler, Matthias, Abdollahi, A., Ammon, A., Aries, S.P., Arntzen, C., Achenbach, H.J., Atanackovic, D., Atmaca, A., Basara, N., Binder, D., Borchard, B., and Bos, M.
- Subjects
LUNG cancer & genetics ,CANCER chemotherapy ,CELL receptors ,CONFIDENCE intervals ,EPIDERMAL growth factor ,LUNG cancer ,GENETIC mutation ,RESEARCH funding ,SURVIVAL analysis (Biometry) ,DATA analysis software ,DESCRIPTIVE statistics ,PROTEIN kinase inhibitors ,THERAPEUTICS - Abstract
Background. Afatinib, an irreversible ErbB family blocker, is approved for treatment of patients with previously untreated non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations. Efficacy of afatinib in EGFR tyrosine kinase inhibitor-naï ve (TKI-naïve) patients with uncommon EGFR mutations (other than exon 19 deletions or exon 21 point mutations) has been reported; however, efficacy in TKI-pretreated patients with uncommon EGFR mutations is unknown. Materials and Methods. In the afatinib compassionate use program (CUP), patients with advanced or metastatic, histologically confirmed NSCLC progressing after at least one line of chemotherapy and one line of EGFR-TKI treatment were enrolled. Demographic data, mutation type, response rates, time to treatment failure (TTF), and safety in patients harboring uncommon EGFR mutations were reported. Results. In 60 patients (63% female, median age 63 years [range: 30-84 years]), a total of 66 uncommon EGFR mutations including 30 T790M mutations were reported (18.4% and 11%, respectively, of known EGFR mutations within the CUP). Most patients (67%) received afatinib as third- or fourth-line treatment. Median TTF was 3.8 months (range: 0.2 to >24.6 months; p = .244) in patients with uncommon mutations compared with 5.1 months (range: 0.1 to >21.1 months) in patients with common mutations (n = 165). Pronounced activity was observed with E709X mutations (TTF >12 months). No new safety signals were detected. Conclusion. Afatinib is clinically active and well tolerated in many TKI-pretreated NSCLC patients harboring uncommon EGFR mutations. Compared with results reported in TKI-naTve patients, activity was also indicated in patients with T790M and exon 20 insertion mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
15. Impact and Safety of Adjuvant Chemotherapy on Pulmonary Function in Early Stage Non-Small Cell Lung Cancer.
- Author
-
Kreuter, Michael, Vansteenkiste, Johan, Herth, Felix J.F., Fischer, Jürgen R., Eberhardt, Wilfried, Zuna, Ivan, Reinmuth, Niels, Griesinger, Frank, and Thomas, Michael
- Subjects
LUNG cancer treatment ,ADVERSE health care events ,CANCER patients ,COMBINED modality therapy ,LUNG cancer ,RESPIRATION ,RESPIRATORY measurements ,PULMONARY function tests ,SAFETY ,OPERATIVE surgery ,TUMOR classification ,DATA analysis ,PROPORTIONAL hazards models ,KAPLAN-Meier estimator ,PREVENTION - Abstract
Background: Pulmonary function may decline after induction chemotherapy and predict perioperative complications in non-small cell lung cancer (NSCLC). The influence of adjuvant chemotherapy is largely indeterminate. Objective: To assess whether adjuvant chemotherapy alters pulmonary function and impacts on treatment-related adverse events. Methods: In a trial on adjuvant chemotherapy (the TREAT trial), 132 patients with R0-resected NSCLC were randomised to 4 cycles of cisplatin-vinorelbine (CVb, n = 65) or cisplatin-pemetrexed (CPx, n = 67). Pulmonary function tests (forced expiratory volume in 1 s, FEV
1 , forced vital capacity, FVC, total lung capacity, TLC, diffusing capacity for carbon monoxide, DLCO, and blood gas analyses, BGA) were analysed before and 30 days after the last chemotherapy, and changes were calculated (Δ = mean differences). Results: Overall,FVC increased significantly (Δ +290 ml, n = 76; p < 0.0001), while TLC did not change (Δ +220 ml, n = 41; p = 0.174). For CPx, FEV1 increased significantly (Δ +150 ml, n = 47; p = 0.0017), but not for CVb (Δ +30 ml, n = 30). DLCO decreased only for CVb (-8%, n = 6) but not for CPx (-0.39%, n = 17; p = 0.58). BGA did not change (p = 0.99). In a Cox regression analysis, baseline pulmonary function did not influence treatment failure. Conclusions: Adjuvant chemotherapy seems not to result in a decrease of pulmonary function parameters. A significant FVC increase was probably due to ongoing postoperative improvement. Decline of DLCO was noted with CVb but not with CPx. Pulmonary function does not impact on treatment failure. © 2013 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
16. Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment – A multicenter analysis.
- Author
-
Frost, Nikolaj, Roeper, Julia, Velthaus, Janna-Lisa, Raspe, Matthias, Olive, Elisabeth, Schmittel, Alexander, Schmidt, Bernd, Wasilewski, David, Onken, Julia, Lüders, Heike, Witzenrath, Martin, Senger, Carolin, Böhmer, Dirk, Loges, Sonja, Griesinger, Frank, Modest, Dominik P., and Grohé, Christian
- Subjects
- *
LUNG cancer , *DISEASE relapse , *NON-small-cell lung carcinoma - Abstract
• Local ablative therapy (LAT) improves survival in oligometastatic lung cancer (OMD) • Retrospective multicenter analysis from 5 certified German Lung Cancer centers. • The initial metastatic site determines the pattern of relapse. • Subsequent LAT for every recurrence is feasible for 25% of all patients. • Intracranial disease control determines survival and correlates to (repeated) LAT. Local ablative therapy (LAT) improves survival in oligometastatic lung cancer (OMD), but there is limited information on recurrence patterns, re-treatments and in particular the role of brain metastases during the course of disease. We therefore conducted a retrospective multicenter analysis to evaluate course of disease, sequence of therapies and predictors for long-term disease-control in the brain and survival endpoints. Clinical data of patients with synchronous, single organ OMD with ≤4 metastases were collected from 5 certified German lung cancer centers. All patients underwent thorough initial staging including a 18FDG-PET/CT scan, brain imaging and mediastinal staging, if necessary, and received LAT to all sites of disease. In total, 164 patients were included (median age 62 years [range 41–84], non-squamous histology 80%, N0-1 64%, single metastasis 84%), 103 had brain (cohort A), 61 extracranial metastases (cohort B). With a median follow-up of 66 months, 115 patients (70%) experienced recurrent disease with a different distribution of sites: In cohort A vs. B, brain relapses occurred in 56% vs. 18% and new distant metastases in 5% vs. 40%. In total, LAT for every relapse was possible for 25% (29/115) of the patients. Patients with initial and secondary onset brain metastases experienced long-term disease-control in the brain and subsequently favorable survival with the application of repeated LAT (disease in the brain controlled vs. not-controlled, HR 0.21, p < 0.001). Comparable long-term overall survival was observed in patients with no or isolated brain relapses (5-years OS 74% and 92%) in contrast to patients with extracranial relapses (5-years OS 19.6%, p < 0.001). Repeated LAT for recurrent synchronous single organ OMD results in a long-term favorable outcome. Disease control in the brain appears crucial and likely determines survival. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery.
- Author
-
Boch, Tobias, Frost, Nikolaj, Sommer, Linna, Overbeck, Tobias R., Michaeli, Christoph T., Szuszies, Chrisoph J., Rieckmann, Lisa-Marie, Beumer, Niklas, Imbusch, Charles D., Winter, Hauke, Thomas, Michael, Roeper, Julia, Janning, Melanie, Griesinger, Frank, Wermke, Martin, and Loges, Sonja
- Subjects
- *
IMMUNOTHERAPY , *IMMUNE checkpoint proteins , *IMMUNE checkpoint inhibitors , *NON-small-cell lung carcinoma , *ACADEMIC medical centers - Abstract
• NSCLC patients with oligometastastic disease benefit from locally ablative and systemic therapy. • Neoadjuvant immunotherapy results in high pCR and MPR rates. • Neoadjuvant immunotherapy is a promising therapeutic concept for oligometastastic disease. Immune checkpoint inhibitors (ICI) have significantly improved outcome of patients with advanced NSCLC and recently also showed benefit in early-stage disease. Patients with oligometastatic disease (OMD) harbor limited metastases, resectable primary tumors and derive benefit from treatment with multimodal locally ablative and systemic therapy approaches. Nothing is known about feasibility and efficacy of neoadjuvant ICI in this setting. We here provide data from a multicenter retrospective study comprising 13 patients with NSCLC and OMD (≤3 distant metastases) from 5 university medical centers in Germany who have been treated with neoadjuvant ICI alone (n = 4) or in combination with chemotherapy (CT) (n = 9) prior to resection of the primary tumor. We analyzed complete (pCR) and major pathological remission (MPR) rates. These data show that neoadjuvant immunotherapy applied mostly in combination with CT results in high rates of pCR and MPR (54 and 69%, respectively). Up to now, 85% of patients are free of progression with a median follow-up of 9 months (3–28 months). Single cell RNASeq analysis of tumor tissue from one patient treated with CT-ICI indicates a strong predominance of adaptive immune cell populations over a small minority of epithelial (tumor) cells. Neoadjuvant ICI with or without CT is a promising therapeutic concept in patients with OMD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. MO19390 (SAiL): Bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC
- Author
-
Dansin, Eric, Cinieri, Saverio, Garrido, Pilar, Griesinger, Frank, Isla, Dolores, Koehler, Manfred, and Kohlhaeufl, Martin
- Subjects
- *
SMALL cell lung cancer , *HEMORRHAGE , *BEVACIZUMAB , *CANCER chemotherapy , *CANCER patients , *SQUAMOUS cell carcinoma , *ANTICOAGULANTS ,CANCER histopathology - Abstract
Abstract: Introduction: The clinical benefit and safety profile associated with first-line bevacizumab with doublet chemotherapy in patients with advanced non-squamous non-small cell lung cancer (NSCLC) was established in two large phase III studies, E4599 and AVAiL. SAiL, a single-arm phase IV study, was conducted to evaluate bevacizumab with a range of first-line chemotherapy regimens in a routine oncology practice setting. Methods: This analysis of the SAiL data was undertaken to specifically evaluate bleeding adverse events (AEs) in this study, and to explore potential associations between bleeding and baseline patient and disease characteristics. Results: In total, 2212 patients were evaluated. Bleeding AEs (any grade) occurred in 38.2% of patients (grade ≥3 bleeding AEs: 3.6%). Grade ≥3 pulmonary hemorrhage and central nervous system bleeding events were observed in 0.7% and 0.1% of patients, respectively. The incidence of grade ≥3 bleeding AEs was comparable across patient subgroups defined by central tumor location, tumor cavitation, histology, concomitant anticoagulation therapy and age. The majority (88.6%) of bleeding events resolved or improved, 10.2% persisted and 1.3% led to death; 10.2% of bleeding events required bevacizumab interruption or discontinuation. Conclusions: This analysis from the SAiL trial reaffirms a comparable incidence of clinically significant bleeding associated with first-line bevacizumab and chemotherapy as previous phase III studies in NSCLC patients despite less stringent first-line selection criteria. Grade ≥3 bleeding appears to be comparable when analyzed for patient and tumor characteristics, including tumor cavitation and concomitant anticoagulation therapy. Most bleeding events resolved or improved, and interruption/discontinuation of bevacizumab was infrequent in a standard oncology practice setting. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.